600557 康缘药业
已收盘 01-08 15:00:00
资讯
新帖
简况
流感需求集中释放催生药企“矩阵式”响应,康缘药业等药企多维布局筑牢健康防线
证券之星 · 01-05
流感需求集中释放催生药企“矩阵式”响应,康缘药业等药企多维布局筑牢健康防线
流感疫情持续,防控系统工程再受考验
证券之星 · 2025-12-31
流感疫情持续,防控系统工程再受考验
康缘药业(600557)披露取消监事会并修改公司章程议案获通过,12月30日股价上涨0.42%
证券之星 · 2025-12-30
康缘药业(600557)披露取消监事会并修改公司章程议案获通过,12月30日股价上涨0.42%
流感季叠加产品矩阵发力 康缘药业中成药业务迎需求窗口期
证券之星 · 2025-12-29
流感季叠加产品矩阵发力 康缘药业中成药业务迎需求窗口期
流感高发带动用药需求 康缘药业打出中医药“组合拳”
证券之星 · 2025-12-29
流感高发带动用药需求 康缘药业打出中医药“组合拳”
流感季来袭,金振口服液成儿童呼吸道感染首选,康缘药业增长韧性凸显
证券之星 · 2025-12-29
流感季来袭,金振口服液成儿童呼吸道感染首选,康缘药业增长韧性凸显
流感季来势汹汹,上市药企如何应考?康缘药业、亿帆医药等多家企业回应
证券之星 · 2025-12-23
流感季来势汹汹,上市药企如何应考?康缘药业、亿帆医药等多家企业回应
流感促中药需求回升 康缘药业散寒化湿颗粒、金振口服液等多个单品集中放量
证券之星 · 2025-12-19
流感促中药需求回升 康缘药业散寒化湿颗粒、金振口服液等多个单品集中放量
康缘药业最新公告:获得泻白散颗粒药品注册证书
证券之星 · 2025-12-12
康缘药业最新公告:获得泻白散颗粒药品注册证书
康缘药业(600557)披露拟取消监事会并增选董事,12月11日股价下跌0.26%
证券之星 · 2025-12-11
康缘药业(600557)披露拟取消监事会并增选董事,12月11日股价下跌0.26%
甲流高发季催生市场需求,康缘药业金振口服液销量激增带动业绩突围
证券之星 · 2025-12-10
甲流高发季催生市场需求,康缘药业金振口服液销量激增带动业绩突围
康缘药业(600557)披露公司部分药品纳入《国家医保目录》,12月9日股价下跌1.42%
证券之星 · 2025-12-09
康缘药业(600557)披露公司部分药品纳入《国家医保目录》,12月9日股价下跌1.42%
康缘药业:12月4日高管潘宇、陈学斌增持股份合计1.1万股
证券之星 · 2025-12-08
康缘药业:12月4日高管潘宇、陈学斌增持股份合计1.1万股
康缘药业最新公告:独家品种温阳解毒颗粒、玉女煎颗粒及国内首家仿制药品种舒马普坦萘普生钠片纳入《国家医保目录》
证券之星 · 2025-12-08
康缘药业最新公告:独家品种温阳解毒颗粒、玉女煎颗粒及国内首家仿制药品种舒马普坦萘普生钠片纳入《国家医保目录》
6个中成药跻身国家医保目录新增名单,康缘、以岭、三九、方盛各有产品入选
智通财经网 · 2025-12-08
6个中成药跻身国家医保目录新增名单,康缘、以岭、三九、方盛各有产品入选
康缘药业:12月3日高管潘宇增持股份合计2000股
证券之星 · 2025-12-05
康缘药业:12月3日高管潘宇增持股份合计2000股
康缘药业:12月1日高管杨永春、刘权增持股份合计1.19万股
证券之星 · 2025-12-03
康缘药业:12月1日高管杨永春、刘权增持股份合计1.19万股
供需两旺!康缘药业呼吸产品矩阵迎流感高峰 中成药成防控“主力”
证券之星 · 2025-12-02
供需两旺!康缘药业呼吸产品矩阵迎流感高峰 中成药成防控“主力”
康缘药业:11月27日至11月28日高管潘宇、陈学斌增持股份合计5000股
证券之星 · 2025-12-01
康缘药业:11月27日至11月28日高管潘宇、陈学斌增持股份合计5000股
流感高发季 康缘药业金振口服液需求明显提升
证券之星 · 2025-11-26
流感高发季 康缘药业金振口服液需求明显提升
加载更多
公司概况
公司名称:
江苏康缘药业股份有限公司
所属行业:
医药制造业
上市日期:
2002-09-18
主营业务:
江苏康缘药业股份有限公司的主营业务是药品的研发、生产与销售。公司的主要产品是金振口服液、热毒宁注射液、杏贝止咳颗粒、温阳解毒颗粒、银杏二萜内酯葡胺注射液、天舒胶囊、天舒片、龙血通络胶囊、桂枝茯苓胶囊、散结镇痛胶囊、复方南星止痛膏、腰痹通胶囊、筋骨止痛凝胶、参乌益肾片、济川煎颗粒。公司是国家技术创新示范企业、国家重点高新技术企业、国家创新型试点企业、国家知识产权示范企业,全国制药工业百强企业。公司积极实施创新驱动战略,建立了国际先进的创新药物研发体系,在新药研发、有效发明专利、承担国家重大科研项目的数量上均居行业领先水平。
发行价格:
7.00
{"stockData":{"symbol":"600557","market":"SH","secType":"STK","nameCN":"康缘药业","latestPrice":14.66,"timestamp":1767855600000,"preClose":14.52,"halted":0,"volume":6483157,"delay":0,"changeRate":0.0096,"floatShares":566000000,"shares":566000000,"eps":0.414,"marketStatus":"已收盘","change":0.14,"latestTime":"01-08 15:00:00","open":14.52,"high":14.7,"low":14.52,"amount":94938100,"amplitude":0.0124,"askPrice":14.66,"askSize":664,"bidPrice":14.65,"bidSize":438,"shortable":0,"etf":0,"ttmEps":0.414,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767922200000},"marketStatusCode":5,"adr":0,"adjPreClose":14.52,"symbolType":"stock","openAndCloseTimeList":[[1767835800000,1767843000000],[1767848400000,1767855600000]],"highLimit":15.97,"lowLimit":13.07,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":566158806,"isCdr":false,"pbRate":1.76,"roa":"--","peRate":35.410628,"roe":"4.33%","epsLYR":0.68,"committee":-0.200681,"marketValue":8300000000,"turnoverRate":0.0115,"status":0,"floatMarketCap":8300000000},"requestUrl":"/m/hq/s/600557","defaultTab":"news","newsList":[{"id":"2601507145","title":"流感需求集中释放催生药企“矩阵式”响应,康缘药业等药企多维布局筑牢健康防线","url":"https://stock-news.laohu8.com/highlight/detail?id=2601507145","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601507145?lang=zh_cn&edition=full","pubTime":"2026-01-05 11:21","pubTimestamp":1767583313,"startTime":"0","endTime":"0","summary":"证券之星 刘凤茹疾控中心数据显示,第50周全国门急诊流感样病例流感阳性率高达50.2%,甲型H3N2亚型占比超95%,儿童、老年及基础疾病人群感染风险显著上升。治疗端是需求释放的核心,已形成层次分明、中西互补的多元化产品矩阵。证券之星注意到,此轮疫情中,华润三九、康缘药业、以岭药业等企业的感冒抗病毒类中成药产品线增长动力强劲。此外,流感会引发高热、咳嗽、咽喉痛等症状,多家上市公司提供对症治疗药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.stockstar.com/SS2026010500010553.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600557","BK0188","BK0028"],"gpt_icon":0},{"id":"2595127727","title":"流感疫情持续,防控系统工程再受考验","url":"https://stock-news.laohu8.com/highlight/detail?id=2595127727","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595127727?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:18","pubTimestamp":1767172695,"startTime":"0","endTime":"0","summary":"2025年末,全国流感疫情持续处于高流行水平。产业链协同响应,构建多层次供应保障流感防控是一项系统工程,需要疫苗预防、快速诊断、药物治疗等多个环节的有效衔接。本轮疫情中,上市药企正通过全产业链布局,搭建从源头预防到终端治疗的健康保障网络。中成药在本轮疫情中表现活跃。公司表示,金振口服液四季度市场需求回暖,正加紧排产满足市场需要。随着该产品儿童流感新适应症的获批,其在儿科领域的应用场景进一步拓宽。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025123100030908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0284","BK0175","BK0239","000756","300244","301207","BK0185","BK0010","BK0074","688276","BK0250","600557","002603","SG9999001069.SGD","BK0236","603858","BK0146","002317","BK0012","002393","BK0097","000999","BK0086","BK0197","600079","600566","BK0201","BK0183","000623","BK0042","BK0070","002728","BK0096","BK0077","BK0164","BK0046","BK0028","BK0114","603882","BK0187","BK0188","300937","BK0186","BK0060"],"gpt_icon":0},{"id":"2595027793","title":"康缘药业(600557)披露取消监事会并修改公司章程议案获通过,12月30日股价上涨0.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595027793","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595027793?lang=zh_cn&edition=full","pubTime":"2025-12-30 17:44","pubTimestamp":1767087894,"startTime":"0","endTime":"0","summary":"截至2025年12月30日收盘,康缘药业报收于14.22元,较前一交易日上涨0.42%,最新总市值为80.51亿元。该股当日开盘14.15元,最高14.28元,最低14.03元,成交额达6301.61万元,换手率为0.79%。会议表决结果均获通过,无否决议案。出席会议股东所持表决权股份占公司总股本的45.0373%。江苏世纪同仁律师事务所对本次会议出具法律意见书,认为会议召集、召开程序及表决结果合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000030257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600557","BK0188","BK0028"],"gpt_icon":0},{"id":"2595782361","title":"流感季叠加产品矩阵发力 康缘药业中成药业务迎需求窗口期","url":"https://stock-news.laohu8.com/highlight/detail?id=2595782361","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595782361?lang=zh_cn&edition=full","pubTime":"2025-12-29 19:26","pubTimestamp":1767007595,"startTime":"0","endTime":"0","summary":"流感的扩散直接激活了药品市场的需求。面对激增的市场需求,康缘药业在呼吸与感染性疾病领域积淀的产品优势正逐步释放。针对流感不同证型和症状,公司另外三款产品形成了有效的补充。面对四季度回暖的市场需求,康缘药业已启动产能响应机制。公司在11月19日的投资者互动中明确表示,“金振口服液等产品四季度市场需求回暖,正加紧排产满足市场需求”。对于康缘药业而言,当前的市场环境为其业绩修复提供了关键契机。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025122900030767.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600557","BK0188","BK0239"],"gpt_icon":0},{"id":"2595789898","title":"流感高发带动用药需求 康缘药业打出中医药“组合拳”","url":"https://stock-news.laohu8.com/highlight/detail?id=2595789898","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595789898?lang=zh_cn&edition=full","pubTime":"2025-12-29 17:52","pubTimestamp":1767001963,"startTime":"0","endTime":"0","summary":"当前,我国流感处于季节性流行期,用药需求持续提升。中药上市公司康缘药业凭借多年积累,打出覆盖全病程的产品矩阵“组合拳”,为患者带来新选择。受此影响,市场对抗流感药物的需求激增,中医药凭借“辨证施治、整体调节”等优势得到关注。康缘药业相关负责人表示,今年四季度,金振口服液等产品需求回暖,公司正加紧排产来满足市场需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.stockstar.com/SS2025122900024808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600557","BK0188","BK0028"],"gpt_icon":0},{"id":"2595378357","title":"流感季来袭,金振口服液成儿童呼吸道感染首选,康缘药业增长韧性凸显","url":"https://stock-news.laohu8.com/highlight/detail?id=2595378357","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595378357?lang=zh_cn&edition=full","pubTime":"2025-12-29 16:31","pubTimestamp":1766997076,"startTime":"0","endTime":"0","summary":"而在儿童呼吸道感染专用药这一相对细分却极具战略价值的赛道中,康缘药业旗下的金振口服液是目前针对流感病毒性感染的药物中,兼具多途径抗病毒与抗炎机制的中药制剂。当前,临床面临流感与多种呼吸道病原体交织感染的复杂局面,其中耐药性问题日益严峻。金振口服液卓越的市场表现,也直接提振了康缘药业的整体经营指标。即使在较高基数下,2024年金振口服液销量仍保持同比增长5.13%的稳健态势,显示出持续的发展韧性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.stockstar.com/SS2025122900020402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","600557","BK0239"],"gpt_icon":0},{"id":"2593463405","title":"流感季来势汹汹,上市药企如何应考?康缘药业、亿帆医药等多家企业回应","url":"https://stock-news.laohu8.com/highlight/detail?id=2593463405","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593463405?lang=zh_cn&edition=full","pubTime":"2025-12-23 11:39","pubTimestamp":1766461198,"startTime":"0","endTime":"0","summary":"流感态势升级药企密集回应近期,流感仍处于高流行水平。疫苗需求的集中释放成为此轮流感季的显著特征。一旦确诊流感,流感患者在发病48小时内及时使用抗病毒药物,可有效缩短病程,降低重症发生率。这一诊疗共识直接带动相关药物需求激增,上市药企纷纷通过互动平台密集披露产品动态,稳定市场预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.stockstar.com/SS2025122300015046.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0070","002019","BK0191","BK0197","600557","BK0185","BK0028","BK0077","BK0239"],"gpt_icon":0},{"id":"2592516221","title":"流感促中药需求回升 康缘药业散寒化湿颗粒、金振口服液等多个单品集中放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2592516221","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592516221?lang=zh_cn&edition=full","pubTime":"2025-12-19 15:59","pubTimestamp":1766131167,"startTime":"0","endTime":"0","summary":"12月19日,记者从康缘药业了解到,公司旗下的散寒化湿颗粒、金振口服液、杏贝止咳颗粒、热毒宁注射液、银翘清热片等品种进入集中放量期。散寒化湿颗粒,带动呼吸产品线提升康缘药业在呼吸系统疾病领域深耕多年,公司研发生产的散寒化湿颗粒、金振口服液、杏贝止咳颗粒、银翘清热片等产品分别对应急性发热、咽痛、湿寒型呼吸道不适、气道炎症及恢复期咳嗽管理,为医生和患者提供了较为细分的用药选择。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025121900018847.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600557","BK0028","BK0188"],"gpt_icon":0},{"id":"2590570939","title":"康缘药业最新公告:获得泻白散颗粒药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2590570939","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590570939?lang=zh_cn&edition=full","pubTime":"2025-12-12 18:31","pubTimestamp":1765535493,"startTime":"0","endTime":"0","summary":"康缘药业(600557.SH)公告称,公司于近日收到国家药品监督管理局签发的泻白散颗粒《药品注册证书》。泻白散颗粒的功能主治为清泻肺热,止咳平喘,用于小儿肺热咳喘证。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200030524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0239","600557"],"gpt_icon":0},{"id":"2590511922","title":"康缘药业(600557)披露拟取消监事会并增选董事,12月11日股价下跌0.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590511922","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590511922?lang=zh_cn&edition=full","pubTime":"2025-12-11 22:08","pubTimestamp":1765462094,"startTime":"0","endTime":"0","summary":"截至2025年12月11日收盘,康缘药业报收于15.15元,较前一交易日下跌0.26%,最新总市值为85.77亿元。该股当日开盘15.16元,最高15.39元,最低15.06元,成交额达9243.48万元,换手率为1.07%。公告显示,公司拟取消监事会,由董事会审计委员会行使监事会职权,并将董事会成员人数由9名增至11名。本次股东会将于2025年12月29日召开,采用现场投票与网络投票相结合的方式,股权登记日为2025年12月22日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100041341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","600557","BK0028"],"gpt_icon":0},{"id":"2590737659","title":"甲流高发季催生市场需求,康缘药业金振口服液销量激增带动业绩突围","url":"https://stock-news.laohu8.com/highlight/detail?id=2590737659","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590737659?lang=zh_cn&edition=full","pubTime":"2025-12-10 09:22","pubTimestamp":1765329762,"startTime":"0","endTime":"0","summary":"近日,康缘药业在投资者互动平台回应市场关切时明确表示,公司核心产品金振口服液凭借“儿童专用+疗效确切”的差异化优势,在本轮甲流疫情中销量实现显著增长,驱动公司业绩稳健增长。销量持续攀升拉动业绩增长康缘药业在回应中披露的经营数据显示,金振口服液的市场表现已成为公司业绩增长的“压舱石”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025121000006110.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600557","BK0239","BK0028","BK0188"],"gpt_icon":0},{"id":"2590231443","title":"康缘药业(600557)披露公司部分药品纳入《国家医保目录》,12月9日股价下跌1.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590231443","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590231443?lang=zh_cn&edition=full","pubTime":"2025-12-09 17:47","pubTimestamp":1765273643,"startTime":"0","endTime":"0","summary":"截至2025年12月9日收盘,康缘药业报收于15.24元,较前一交易日下跌1.42%,最新总市值为86.28亿元。该股当日开盘15.43元,最高15.55元,最低15.23元,成交额达1.02亿元,换手率为1.17%。近日,江苏康缘药业股份有限公司发布公告称,根据国家医保局于2025年12月7日发布的《国家医保目录》,公司独家品种温阳解毒颗粒、玉女煎颗粒及国内首家仿制药品种舒马普坦萘普生钠片首次通过谈判纳入目录。公司共有123个品种纳入《国家医保目录》,其中甲类48个,乙类75个。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900027745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0239","600557"],"gpt_icon":0},{"id":"2589370033","title":"康缘药业:12月4日高管潘宇、陈学斌增持股份合计1.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2589370033","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589370033?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:03","pubTimestamp":1765195395,"startTime":"0","endTime":"0","summary":"证券之星消息,根据12月8日市场公开信息、上市公司公告及交易所披露数据整理,康缘药业最新董监高及相关人员股份变动情况:2025年12月4日公司高级管理人员潘宇、董事陈学斌共增持公司股份1.1万股,占公司总股本为0.0019%。变动期间公司股价下跌0.2%,12月4日当日收盘报15.1元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800029551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600557","BK0239","BK0188","BK0028"],"gpt_icon":0},{"id":"2589334845","title":"康缘药业最新公告:独家品种温阳解毒颗粒、玉女煎颗粒及国内首家仿制药品种舒马普坦萘普生钠片纳入《国家医保目录》","url":"https://stock-news.laohu8.com/highlight/detail?id=2589334845","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589334845?lang=zh_cn&edition=full","pubTime":"2025-12-08 18:39","pubTimestamp":1765190374,"startTime":"0","endTime":"0","summary":"康缘药业(600557.SH)公告称,公司独家品种温阳解毒颗粒、玉女煎颗粒,以及国内首家仿制药品种舒马普坦萘普生钠片首次通过谈判纳入《国家基本医疗保险、生育保险和工伤保险药品目录(2025年版)》。其中,温阳解毒颗粒和玉女煎颗粒为中药新药,分别用于治疗疫病辨证属阳气虚弱和胃热阴虚证;舒马普坦萘普生钠片为化学药品3类,用于成人有或无先兆偏头痛的急性治疗。此次纳入医保预计将推动公司新药市场推广与销售增长,但对公司业绩的短期影响暂无法估计。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800024584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","600557","BK0239"],"gpt_icon":0},{"id":"2589803385","title":"6个中成药跻身国家医保目录新增名单,康缘、以岭、三九、方盛各有产品入选","url":"https://stock-news.laohu8.com/highlight/detail?id=2589803385","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589803385?lang=zh_cn&edition=full","pubTime":"2025-12-08 11:31","pubTimestamp":1765164685,"startTime":"0","endTime":"0","summary":"根据国家医保局披露的名单,此次新增的6个中成药品种分别为:温阳解毒颗粒、参郁宁神片、养血祛风止痛颗粒、益气清肺颗粒、玉女煎颗粒、芪防鼻通片,其中包括3个1.1类新药,3个3类新药。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20251208/20251208113159_33210.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251208/20251208113159_33210.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"6个中成药跻身国家医保目录新增名单,康缘、以岭、三九、方盛各有产品入选","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0060","BK0175","BK0012","BK0028","000999","BK0042","BK0188","BK0185","BK0196","002603","603998","BK0046","BK0097","BK0010","600557","BK0239","BK0183"],"gpt_icon":0},{"id":"2589695894","title":"康缘药业:12月3日高管潘宇增持股份合计2000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2589695894","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589695894?lang=zh_cn&edition=full","pubTime":"2025-12-05 20:03","pubTimestamp":1764936184,"startTime":"0","endTime":"0","summary":"证券之星消息,根据12月5日市场公开信息、上市公司公告及交易所披露数据整理,康缘药业最新董监高及相关人员股份变动情况:2025年12月3日公司高级管理人员潘宇共增持公司股份2000.0股,占公司总股本为0.0004%。康缘药业近半年内的董监高及核心技术人员增减持详情如下:康缘药业的高管列表及最新持股情况如下:融资融券数据显示该股近5日融资净流入440.42万,融资余额增加;融券净流出2.5万,融券余额减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500034769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0028","600557"],"gpt_icon":0},{"id":"2588045809","title":"康缘药业:12月1日高管杨永春、刘权增持股份合计1.19万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588045809","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588045809?lang=zh_cn&edition=full","pubTime":"2025-12-03 20:03","pubTimestamp":1764763400,"startTime":"0","endTime":"0","summary":"证券之星消息,根据12月3日市场公开信息、上市公司公告及交易所披露数据整理,康缘药业最新董监高及相关人员股份变动情况:2025年12月1日公司董事,高级管理人员杨永春、高级管理人员刘权共增持公司股份1.19万股,占公司总股本为0.0021%。康缘药业近半年内的董监高及核心技术人员增减持详情如下:康缘药业的高管列表及最新持股情况如下:融资融券数据显示该股近5日融资净流入55.41万,融资余额增加;融券净流出4.9万,融券余额减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300034922.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600557","BK0239","BK0188","BK0028"],"gpt_icon":0},{"id":"2588036230","title":"供需两旺!康缘药业呼吸产品矩阵迎流感高峰 中成药成防控“主力”","url":"https://stock-news.laohu8.com/highlight/detail?id=2588036230","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588036230?lang=zh_cn&edition=full","pubTime":"2025-12-02 17:22","pubTimestamp":1764667353,"startTime":"0","endTime":"0","summary":"康缘药业在投资者互动平台中透露,公司呼吸与感染疾病产品线已形成完整矩阵,覆盖从预防到治疗、从儿童到成人的多类症状需求。事实上,康缘药业近年来着力构建的呼吸与感染疾病产品矩阵正在此轮疾病高峰中发挥协同效应。康缘药业通过多年来在呼吸系统疾病领域的产品布局与临床投入,已在当前疾病高发期展现出强劲的产品能力与市场应变能力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025120200025671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600557","BK0188","BK0028","BK0239"],"gpt_icon":0},{"id":"2588722887","title":"康缘药业:11月27日至11月28日高管潘宇、陈学斌增持股份合计5000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588722887","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588722887?lang=zh_cn&edition=full","pubTime":"2025-12-01 20:02","pubTimestamp":1764590568,"startTime":"0","endTime":"0","summary":"证券之星消息,根据12月1日市场公开信息、上市公司公告及交易所披露数据整理,康缘药业最新董监高及相关人员股份变动情况:2025年11月27日至2025年11月28日公司高级管理人员潘宇、董事陈学斌共增持公司股份5000.0股,占公司总股本为0.0009%。变动期间公司股价下跌2.46%,11月28日当日收盘报15.08元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100030975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600557","BK0239","BK0188"],"gpt_icon":0},{"id":"2586853242","title":"流感高发季 康缘药业金振口服液需求明显提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2586853242","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586853242?lang=zh_cn&edition=full","pubTime":"2025-11-26 09:10","pubTimestamp":1764119409,"startTime":"0","endTime":"0","summary":"针对这一临床痛点,康缘药业于2023年公布的金振口服液联合阿奇霉素治疗儿童肺炎支原体肺炎的循证医学研究,提供了新的解决方案。基于在支原体肺炎领域建立的高级别证据,康缘药业正尝试进一步拓展金振口服液的适应症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025112600004672.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600557","BK0028","BK0188"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767875012903,"stockEarnings":[{"period":"1week","weight":0.0291},{"period":"1month","weight":-0.0608},{"period":"3month","weight":-0.0447},{"period":"6month","weight":-0.0931},{"period":"1year","weight":0.0934},{"period":"ytd","weight":0.0291}],"compareEarnings":[{"period":"1week","weight":0.0295},{"period":"1month","weight":0.0412},{"period":"3month","weight":0.0386},{"period":"6month","weight":0.164},{"period":"1year","weight":0.2651},{"period":"ytd","weight":0.0295}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏康缘药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"40529人(较上一季度增加17.20%)","perCapita":"13969股","listingDate":"2002-09-18","address":"江苏省连云港市连云区经济技术开发区江宁工业城","registeredCapital":"56615万元","survey":" 江苏康缘药业股份有限公司的主营业务是药品的研发、生产与销售。公司的主要产品是金振口服液、热毒宁注射液、杏贝止咳颗粒、温阳解毒颗粒、银杏二萜内酯葡胺注射液、天舒胶囊、天舒片、龙血通络胶囊、桂枝茯苓胶囊、散结镇痛胶囊、复方南星止痛膏、腰痹通胶囊、筋骨止痛凝胶、参乌益肾片、济川煎颗粒。公司是国家技术创新示范企业、国家重点高新技术企业、国家创新型试点企业、国家知识产权示范企业,全国制药工业百强企业。公司积极实施创新驱动战略,建立了国际先进的创新药物研发体系,在新药研发、有效发明专利、承担国家重大科研项目的数量上均居行业领先水平。","listedPrice":7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康缘药业(600557)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康缘药业(600557)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康缘药业,600557,康缘药业股票,康缘药业股票老虎,康缘药业股票老虎国际,康缘药业行情,康缘药业股票行情,康缘药业股价,康缘药业股市,康缘药业股票价格,康缘药业股票交易,康缘药业股票购买,康缘药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康缘药业(600557)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康缘药业(600557)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}